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The aim of study was to compare patients with hypertrophic cardiomyopathy divided according to septal configuration assessed in
a 4-chamber apical window. The study group consisted of 56 consecutive patients. Reversed septal curvature (RSC) and non-RSC
were diagnosed in 17 (30.4%) and 39 (69.6%) patients, respectively. Both RSC and non-RSC groups were compared in terms of the
level of high-sensitivity troponin I (hs-TnI), NT-proBNP (absolute value), NT-proBNP/ULN (value normalized for sex and age),
and echocardiographic parameters, including left ventricular outflow tract gradient (LVOTG). A higher level of hs-TnI was
observed in RSC patients as compared to the non-RSC group (102 (29.2-214.7) vs. 8.7 (5.3-18) (ng/l), p = 0:001). A trend
toward increased NT-proBNP value was reported in RSC patients (1279 (367.3-1186) vs. 551.7 (273-969) (pg/ml), p = 0:056).
However, no difference in the NT-proBNP/ULN level between both groups was observed. Provocable LVOTG was higher in
RSC as compared to non-RSC patients (51 (9.5-105) vs. 13.6 (7.5-31) (mmHg), p = 0:04). Furthermore, more patients with RSC
had prognostically unfavourable increased septal thickness to left LV diameter at the end diastole ratio. Patients with RSC were
associated with an increased level of hs-TnI, and the only trend observed in this group was for the higher NT-proBNP levels.
RSC seems to be an alerting factor for the risk of ischemic events. Not resting but only provocable LVOTG was higher in RSC
as compared to non-RSC patients.
1. Introduction
Monitoring of biomarkers including troponin (Tn) and N-
terminal pro-B-type NT-pronatriuretic peptide (NT-proBNP)
might be utilized in the clinical evaluation, management, and
prognosis of patients with hypertrophic cardiomyopathy
(HCM) [1]. Recently reported papers have studied the
importance of very short time synchronization in the
sampling of echocardiographic parameters and cardiac bio-
markers in HCM [2, 3]. The strategy of these studies was
based on performing transthoracic echocardiography
(TTE) and evaluation of hs-troponin I and NT-proBNP as
close to each other as possible. Such tactic guarantees that
currently detected ischemia is related to actual myocardial
functional/dynamic status with provoked left ventricular
outflow tract gradient (LVOTG) as an equivalent. This pro-
tocol is crucial to obtain reliable results of this unstable
parameter. Provocation of higher LVOTG is strongly asso-
ciated with increased myocardial oxygen consumption
inducing ischemia [4, 5]. The strategy of simultaneous mea-
surement of the relationship between gradient provocation
and ischemia induction was confirmed in invasive studies
[4, 5]. Thus, the potential relationship between current
ischemia (probably frequently repeated in past history)
and echocardiographic stabile septal configuration predis-
posing to myocardial ischemia (possibly even during all
the life span) should be evaluated. This echocardiographic
abnormal configuration is reversed septal curvature (RSC)
visualized in 4-chamber apical view. Importantly, a patho-
morphological study revealed that RSC occurs more
frequently in young than in elderly victims of sudden car-
diac death (SCD) [6]. This fact might suggest that majority
of patients with RSC configuration died prematurely proba-
bly due to ischemia-provoked ventricular fibrillation. In a
Hindawi
Disease Markers
Volume 2020, Article ID 8821961, 6 pages
https://doi.org/10.1155/2020/8821961
previous study, RSC was considered as a risk factor for SCD
in HCM [7]. Thus, we sought to compare both RSC and
non-RSC groups in terms of the biomarker level and echo-
cardiographic parameters, including LVOTG.
2. Materials and Methods
The group of adult 56 consecutive patients with HCM
was enrolled to study analysis after several exclusions.
The study protocol was approved by the local ethics commit-
tee board (Bioethics Committee of Jagiellonian University
KBET/119/B/2017). All included patients provided written
informed consent to participate in the study. The study pro-
tocol conforms to the ethical guidelines of the 1975 Declara-
tion of Helsinki with later amendments. All analysed patients
fulfilled diagnostic criteria for HCM [8]. The standard defini-
tion in adult patients was used to recognize HCM with TTE
parameter evaluation ([8]. Patients with (n = 40) or without
(n = 16) prescribed treatment (newly diagnosed patients
referred to our ambulatory clinic) were examined by TTE
with LVOT gradient provocation by two natural stimuli
(orthostatic test and the Valsalva test) [8–10]. Exclusion cri-
teria were as follows: ST-segment or non-ST-segment eleva-
tion myocardial infarction (current or previous), significant
coronary stenosis in recent coronary angiography, previous
alcohol septal ablation, dilated LV cavity and decreased LV
contractibility, atrial fibrillation, and arterial hypertension.
Only patients with LV ejection fraction > 50% were enrolled.
Furthermore, renal failure is a typical extracardiac factor
related to TnI elevation. To overcome potential bias
related to this factor, patients with elevated serum creati-
nine levels resulting in estimated glomerular filtration
rate < 60ml/min/1.73m2 were excluded from the study group.
We performed genetic analysis with positive findings
only in part of our patients [11]. According to Bos et al.
[12], univariate and multivariate analyses demonstrated
echocardiographic RSC, age at diagnosis < 45 years, maximal
LVWT ≥ 20mm, family history of HCM, and family history
of SCD to be positive predictors of the positive genetic test
while hypertension was a negative predictor. All our patients
had at least one above-mentioned predictor of the positive
genetic test, and the negative predictor was excluded.
Several storage diseases were excluded using the follow-
ing criteria. Fabry disease was excluded by the absence of
clinical signs and symptoms: acroparesthesis, angiokerato-
mas, anhydrosis, and renal dysfunction—proteinuria and
lower filtration rate. Finally, in suspected patients, enzymatic
analysis was performed. Pompe or Danon diseases were
excluded by the following exclusive criteria: (1) patients
below 18 years of age, (2) muscle weakness, skeletal myopa-
thy, and (3) elevation of creatine kinase. Apart from storage
disease, patients treated with steroids or tacrolimus were
excluded.
Only patients with coronary microvessel disease, which
might be common in HCM at any age, were enrolled in the
study group (inclusion criteria: normal/near-normal coro-
nary arteries or no indication of coronary arteriography).
Almost all patients with CCS III class (n = 9/10) and one with
CCS IV (n = 1/1) underwent coronary angiography. Most of
the patients have not undergone coronary angiography
(young, without angina, and without risk factors for
CAD—especially without diabetes mellitus). The probability
of CAD was low; thus, there was no clinical indication to per-
form coronary angiography. Diabetes mellitus is associated
with silent ischemia from epicardial coronary arteries; thus,
it was necessary to exclude painless macrovascular disease
[13]. All included patients were compared according to septal
curvature assessed in 4-chamber apical view. There were 39
patients in the subgroup with nonreversed septal curvature
(non-RSC) and 17 patients with RSC (Figure 1).
In the non-RSC subgroup, there were basic septal, neutral
(no convex/no concave toward LV cavity), and no apical
variant. Additionally, we analysed the ratio of septal thick-
ness divided by LV diameter at end diastole moment
(STD/LVEDD). This ratio was calculated using echocardio-
graphic parameters measured in long-axis parasternal
view. STD was measured also in short-axis parasternal
view (if STD was greater than 2mm (few cases), the
patient was excluded) [7]. Patients were also excluded if
maximal LV thickness was located out of the septal sector
(2 patients). These patients after comprehensive analysis
Figure 1: Reversed septal curvature. Predominant midseptal convexity toward left ventricle cavity; crescent-shaped cavity.
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were rediagnosed as Fabry disease. This parameter is linked
to an unfavourable prognosis when the result is above 0.5
[7]. Furthermore, both RSC and non-RSC groups were
compared in terms of the level of high-sensitivity troponin
I (hs-TnI), NT-proBNP (absolute value), and NT-proBNP/
ULN (value normalized for sex and age). A cut-off value of
19 ng/l was used according to the manufacturer’s instructions
(biometry VIDAS® high-sensitivity troponin I). This value
represents the 99th percentile of a presumably healthy popu-
lation. High-sensitivity troponin tests were performed with
the use of the VIDAS high-sensitivity troponin I (TNHS).
The test is capable of measuring cardiac troponin I concen-
tration in the range of 4.9-40,000.00 pg/ml (ng/1) without
the need for dilution. The level of NT-proBNP was evaluated
with the use of an Elecsys proBNP II Cobas e601 system. The
test is able to measure the NT-proBNP concentration in the
range of 5–35,000 pg/ml without the need for dilution. The
NT-proBNP levels were presented as absolute values and
standardized to sex and age on the basis of the manufac-
turer’s guidelines (http://www.rochecanada.com/content/dam/
roche_canada/en_CA/documents/package_inserts/ProBNPII-
04842464190-EN-V9-CAN.pdf). The value of NT-proBNP
above the 95th percentile for age and gender (the ULN) was
considered abnormal. Therefore, the results were expressed
as the ratio of the NT-proBNP to age- and sex-matched
ULN. Rate > 1:0 was considered to be abnormal [14]. This
standardization of NT-proBNP provides a normal distribu-
tion of data, whereas absolute values were distributed
abnormally. Thus, there was no need for logarithmic transfor-
mation for artificial calculation. Standard descriptive statistics
were used. Quantitative variables were expressed as the mean
and standard deviation (SD) (normally distributed data—
Kolmogorov-Smirnov) or median and interquartile range
(IQR) (abnormal distribution of data). Categorical variables
were presented with counts and as percentages (Fisher exact
or Chi-squared test). Differences between two groups were
evaluated using an independent t-test or Mann-Whitney-
Wilcoxon test dependent on distribution of data. The results
were considered significant at p value of 0.05 or lower. All sta-
tistical analyses were performed using STATISTICA v 13
software (StatSoft, Inc., Kraków, Poland).
3. Results
The study group included 30 men and 26 women. The mean
age of all patients was 45 ± 6 (years). Most of them was on
treatment—31 (55%) on beta-blockers, 19 (34%) on verapa-
mil, and 6 (11%) on diuretics. Baseline clinical data is pre-
sented in Table 1. Almost all patients with CCS III class
(n = 9/10) and one with CCS IV (n = 1/1) underwent coro-
nary angiography. RSC was related to CCS III/IV. A higher
level of hs-TnI was observed in RSC patients as compared
to the non-RSC group. A trend toward increased NT-
proBNP value was reported in RSC patients. However, no
difference in the NT-proBNP/ULN level was observed
between both groups (Table 2). In TTE parameters, the
RSC group was characterized by a higher value of provocable
LVOTG as compared to non-RSC patients; however, similar
resting LVOT was observed. In M-mode measurements, STD
was greater and LVEDD was smaller in RSC vs. non-RSC;
thus, STD/LVEDD > 0:5 was more frequently reported in
the RSC subgroup (Table 2). There was a higher rate of nsVT,
syncope, and family history of SCD in the RSC group
(Table 2).
Patients with non-RSC had more than twice lower risk of
SCD according to the ESC calculator (3.09 (1.9-4.76) vs. 8.83
(4.37-12.35) (%/5 years), p = 0:002) (Table 2). In addition, in
the RSC subgroup, majority of patients were at high risk of
SCD according to the ESC risk calculator (>6%/5 years vs.
<4%/5 years: 53% vs. 18%, p = 0:007).
4. Discussion
The results of our analysis suggest that patients with RSC
were associated with an increased level of hs-TnI. Addition-
ally, a trend was observed in this group for the higher NT-
proBNP but not in NT-proBNP levels. RSC seems to be an
alerting, morphological sign related to ischemic events. Only
provocable LVOTG was higher in RSC as compared to non-
RSC patients. Furthermore, more patients with RSC had a
prognostically unfavourable increased STD/LVEDD ratio
[7]. In a pioneered paper by Lever et al., the RSC with
crescent LV cavity size was detected only in younger HCM
patients [15]. Analysing the relationship between age
and RSC in a pathomorphological study [6], advanced
Table 1: Baseline characteristics of the patients.
NYHA
Class I 6 (11%)
Class II 26 (46%)
Class III/IV 24 (43%)
CCS
Class I 25 (45%)
Class II 20 (36%)
Class III/IV 11 (19%)
Syncope (n) 23 (41%)
Sudden death in family history (n) 22 (39%)
NSVT in Holter (n) 24 (43%)







Systolic pulmonary artery pressure (mmHg) 35:4 ± 14:7
Maximum LV thickness (mm) 22:6 ± 4:9
Resting LVOT gradient ≥ 30mmHg (n) 14
Provocable LVOT gradient ≥ 30mmHg (n) 12
Left atrial diameter (cm), mean (SD) 4:89 ± 0:81
Data are presented as the number (percentage) or mean and standard
deviation. CCS: Canadian Cardiovascular Society; EF: ejection fraction;
LVOT: left ventricular outflow tract; LV: left ventricular; NSVT:
nonsustained ventricular tachycardia; NYHA: New York Heart Association.
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abnormality in myocardial architecture (strongly related to
reversed RSC) was common in patients who died at a mean
age of 25 years. In contrast, most of the patients who were
older than 65 years when they died had a normal circular unit
surrounding the LV cavity as a morphological marker of
non-RSC. Hypothetically, SCD may be related to RSC via
repetitive ischemic episodes. To evaluate the cumulative
effect of both increased septal hypertrophy and decreased
LV cavity size, we used the proportion of two TTE parame-
ters measured at end diastole (the ratio of septal thickness
to left ventricular diastolic diameter (STD/LVEDD)). In
searching for other morphological substrates that culminate
in the STD/LVEED ratio as SCD risk factors, we hypothe-
sised that a small LV cavity might be a predictor of SCD
because it is often linked with several risk factors (from dif-
ferent guidelines) for SCD, syncope [16], abnormal blood
pressure response to exercise [17], and massive LV hypertro-
phy [18]. A narrow LV cavity easily predisposes to hypoten-
sive mediated syncope during LV low input-low output
failure triggered by tachycardia [19]. It was postulated that
the combination of low filling volume and nonsustained ven-
tricular tachycardia (nsVT) might lead to sudden depression
of cardiac output with severe hypotension [19]. Thus, ven-
tricular fibrillation might be triggered as the cumulative effect
of myocardial ischemia (due to hypotension mediated reduc-
tion of coronary perfusion) and electrical instability. In a
recently published study [20], authors have defined two
subgroups of HCM patients: the first subgroup had RSC
morphology with more fibrosis, but less resting obstruction,
whereas the second subgroup presented non-RSC configura-
tion with more frequent obstruction occurrence and less
fibrosis. The authors postulated the need for further investi-
gation comparing these subgroups to search for risk factors
for SCD. This reasonable conception had been partially veri-
fied in the year 2005 in a small-scale study [7] where RSC had
been recognized as a risk cofactor for SCD. In our opinion,
the lack of provoked obstruction in all included patients
might limit observed results. The European Society of Cardi-
ology (ESC) risk score of SCD recommended the use of
maximal-provocable LVOT gradient rather than the resting
one [8]. Importantly, in this study, we have documented that
the maximized value of provocable LVOT gradient was asso-
ciated with an increased level of high-sensitivity troponin [4].
In another study [20], the positive troponin test corre-
sponded with a higher ESC risk score of SCD as compared
to patients with a negative troponin test estimated according
to the SCD calculator (including provocable LVOT gradient
as a component) (6:38% ± 4:17% vs. 3:81% ± 3:23%, p <
0:05). Furthermore, the authors stated that TTE examination
should be performed as close as possible to the moment of
enrollment. It created unfavourable delay for biomarker
assessment. In contrast, we stressed that TTE and biomarker
sampling/measurement must be close to each other as possi-
ble [2, 3]. The strategy of simultaneous measurement of the
relationship between gradient provocation and ischemia
induction was also effectively used in the invasive study
[4, 5]. The pathophysiological mechanism behind ischemia
in RSC is still elusive. However, RSC patients have a
higher volume of postcontrast hyperenhancement in MRI
study suggesting a greater amount of ischemical necrosis
[19]. The RSC generating catenoid shape of the septum
might lead to septal immobility because a ventricular seg-
ment with a net zero curvature would develop internal
tension with no isometric contraction. Adjacent fiber
tracts with opposite curvatures would develop maximum
tension without motion. This process is connected with
high energy consumption/demand and easily provokes
myocardial ischemia [21].
There were patients with (n = 40) or without (n=16)
prescribed treatment (newly diagnosed patients referred to
our ambulatory clinic). Our group was mixed as concerned
to therapy. After our study assessment, the therapy was
Table 2: Comparison of patients with reversed septal curvature and nonreversed septal curvature.
RSC (n = 17) Non-RSC (n = 39) p value
hs-TnI (ng/l) 102 (29.2-214.7) 8.7 (5.3-18) 0.001
NT-proBNP (pg/ml) 1279 (367.3-1186) 551.7 (273-969) 0.056
NT-proBNP/ULN 6:51 ± 4:87 4:59 ± 4:23 0.14
LVOTG at rest (mmHg) 10 (6.47-52) 8.2 (5.4-21) 0.3
LVOTG provocable (mmHg) 51 (9.5-105) 13.6 (7.5-31) 0.04
STD (mm) 24:1 ± 5:3 19:8 ± 3:4 0.02
LVEDD (mm) 35:3 ± 6:6 42:1 ± 5:2 0.001
STD/LVEDD > 0:5 14/17 (82%) 9/39 (18%) 0.001
EF (%) 61:2 ± 9:8 63:4 ± 9:5 0.7
Systolic pulmonary artery pressure (mmHg) 38:3 ± 16:6 33:7 ± 13:5 0.3
nsVT 11/17 (65.7%) 13/39 (33.3%) 0.02
Syncope 11/17 (65%) 12/39 (31%) 0.02
Family history of SCD 10/17 (59%) 12/39 (31%) 0.04
Risk of SCD at 5 years (%) 8.83 (4.37-12.35) 3.09 (1.9-4.76) 0.002
Data are presented as the mean and standard deviation or median and interquartile range. EF: ejection fraction; LVEDD: left ventricular end-diastolic diameter;
LVOTG: left ventricular outflow tract gradient; nsVT: nonsustained ventricular tachycardia; SCD: sudden cardiac death; STD: septal thickness at end diastole.
4 Disease Markers
introduced or improved especially in NYHA III/IV. The
number of patients is too low to assess the relationship
with RSC.
5. Limitations
The most important limitation of this study is the relatively
small number of patients related to several exclusion criteria.
Most of the patients have not met clinical indications for
coronary angiography (young, without angina pectoris, and
without risk factors for CAD). The risk for CAD was low;
thus, coronary angiography was not indicated (unfortu-
nately, multislice coronary computed tomography was not
performed). The strategy of noninvasive identification of
subgroups with a low likelihood of obstructive CAD is effec-
tive [22]. Slightly higher troponin might be not a result of
myocardial ischemia; however, very detailed exclusion cri-
teria and use of the high-sensitivity troponin I test may assure
that troponin was released by ischemic event. There is a pos-
sible bias related to insufficient sample size. We were not able
to calculate multivariable regression analysis.
The next problem related to the small number of patients
is the fact that the value of NT-proBNP was elevated in both
subgroups, but differences were on the border of statistical
significance.
Thus, the result of this study is rather hypothesis-
generating than causative. However, a study with a large
group of patients might be able to achieve statistically signif-
icant differences.
6. Conclusion
Ischemia detected by an elevated troponin level in HCM
patients might be strongly related to abnormal septal config-
uration. RSC as an unchangeable (during many years) feature
seems to be an alerting signal of risk of ischemic events. The
RSC subgroup was linked to a higher rate of nsVT, syncope,
and family history of SCD.
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